{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T07:05:55Z","timestamp":1776323155333,"version":"3.50.1"},"reference-count":51,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T00:00:00Z","timestamp":1634947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>The importance of closely observing patients receiving antibiotic therapy, performing therapeutic drug monitoring (TDM), and regularly adjusting dosing regimens has been extensively demonstrated. Additionally, antibiotic resistance is a contemporary concerningly dangerous issue. Optimizing the use of antibiotics is crucial to ensure treatment efficacy and prevent toxicity caused by overdosing, as well as to combat the prevalence and wide spread of resistant strains. Some antibiotics have been selected and reserved for the treatment of severe infections, including amikacin, gentamicin, tobramycin, and vancomycin. Critically ill patients often require long treatments, hospitalization, and require particular attention regarding TDM and dosing adjustments. As these antibiotics are eliminated by the kidneys, critical deterioration of renal function and toxic effects must be prevented. In this work, clinical data from a Portuguese cohort of 82 inpatients was analyzed and physiologically based pharmacokinetic (PBPK) modeling and simulation was used to study the influence of different therapeutic regimens and parameters as biological sex, body weight, and renal function on the biodistribution and pharmacokinetic (PK) profile of these four antibiotics. Renal function demonstrated the greatest impact on plasma concentration of these antibiotics, and vancomycin had the most considerable accumulation in plasma over time, particularly in patients with impaired renal function. Thus, through a PBPK study, it is possible to understand which pharmacokinetic parameters will have the greatest variation in a given population receiving antibiotic administrations in hospital context.<\/jats:p>","DOI":"10.3390\/life11111130","type":"journal-article","created":{"date-parts":[[2021,10,24]],"date-time":"2021-10-24T22:07:11Z","timestamp":1635113231000},"page":"1130","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["PBPK Modeling and Simulation of Antibiotics Amikacin, Gentamicin, Tobramycin, and Vancomycin Used in Hospital Practice"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3271-6444","authenticated-orcid":false,"given":"Abigail","family":"Ferreira","sequence":"first","affiliation":[{"name":"OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"LAQV\/REQUIMTE, Laboratory of Applied Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal"}]},{"given":"Helena","family":"Martins","sequence":"additional","affiliation":[{"name":"Departament of Pathology, Clinical Chemistry Service, Centro Hospitalar Universit\u00e1rio do Porto (CHUP), 4099-001 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2142-6839","authenticated-orcid":false,"given":"Jos\u00e9 Carlos","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Departament of Pathology, Clinical Chemistry Service, Centro Hospitalar Universit\u00e1rio do Porto (CHUP), 4099-001 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6980-0522","authenticated-orcid":false,"given":"Rui","family":"Lapa","sequence":"additional","affiliation":[{"name":"LAQV\/REQUIMTE, Laboratory of Applied Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[{"name":"OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,23]]},"reference":[{"key":"ref_1","unstructured":"Clarke, W., and Dasgupta, A. (2016). Clinical Challenges in Therapeutic Drug Monitoring: Special Populations, Physiological Conditions and Pharmacogenomics, Elsevier Science."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","article-title":"Overview of therapeutic drug monitoring","volume":"24","author":"Kang","year":"2009","journal-title":"Korean J. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fphar.2020.00177","article-title":"The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib","volume":"11","author":"Buclin","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.ejca.2014.04.015","article-title":"Review of therapeutic drug monitoring of anticancer drugs part two-Targeted therapies","volume":"50","author":"Widmer","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40265-018-0880-z","article-title":"Therapeutic Drug Monitoring of Beta-Lactams and Other Antibiotics in the Intensive Care Unit: Which Agents, Which Patients and Which Infections?","volume":"78","author":"Muller","year":"2018","journal-title":"Drugs"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2174\/1570162X17666190903232053","article-title":"Benefits and Limits of Antiretroviral Drug Monitoring in Routine Practice","volume":"17","author":"Maitre","year":"2019","journal-title":"Curr. HIV Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/BOR.0000000000000713","article-title":"Therapeutic drug monitoring in patients on biologics: Lessons from gastroenterology","volume":"32","author":"Papamichael","year":"2020","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/15622975.2018.1439595","article-title":"TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians","volume":"19","author":"Schoretsanitis","year":"2018","journal-title":"World J. Biol. Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4065\/mcp.2010.0639","article-title":"General Principles of Antimicrobial Therapy","volume":"86","author":"Leekha","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: A Position Paper","volume":"46","author":"Alffenaar","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s10096-019-03769-8","article-title":"Diagnostic and medical needs for therapeutic drug monitoring of antibiotics","volume":"39","author":"Mabilat","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/cpt.2202","article-title":"From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotics","volume":"109","author":"Wicha","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.2147\/IDR.S208783","article-title":"A nationwide utilization survey of therapeutic drug monitoring for five antibiotics in South Korea","volume":"12","author":"Choi","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1111\/j.1365-2125.2001.00377.x","article-title":"The therapeutic monitoring of antimicrobial agents","volume":"52","author":"Begg","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1093\/jac\/dkw408","article-title":"Therapeutic drug monitoring in the past 40 years of the Journal of Antimicrobial Chemotherapy","volume":"71","author":"Reeves","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0025-7125(05)70309-6","article-title":"Antibiotic side effects","volume":"85","author":"Cunha","year":"2001","journal-title":"Med. Clin. N. Am."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bcp.2016.10.005","article-title":"Antibiotics: Pharmacokinetics, toxicity, resistance and multidrug efflux pumps","volume":"133","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00228-019-02644-x","article-title":"Monitoring of tobramycin serum concentrations in selected critically ill patients receiving selective decontamination of the digestive tract: A retrospective evaluation","volume":"75","author":"Mascini","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jcf.2006.05.015","article-title":"Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations","volume":"6","author":"Coulthard","year":"2007","journal-title":"J. Cyst. Fibros."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Ye, Z.K., Tang, H.L., and Zhai, S.D. (2013). Benefits of therapeutic drug monitoring of vancomycin: A systematic review and meta-analysis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0077169"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/491712","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak","year":"2006","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am. J. Health Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1093\/jac\/dkw250","article-title":"Amikacin use and therapeutic drug monitoring in adults: Do dose regimens and drug exposures affect either outcome or adverse events? A systematic review","volume":"71","author":"Jenkins","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4103\/0976-0105.183260","article-title":"Therapeutic monitoring of amikacin and gentamicin in critically and noncritically ill patients","volume":"7","author":"Avram","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.phrs.2018.07.005","article-title":"Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives","volume":"134","author":"Mouton","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/FTD.0000000000000432","article-title":"Therapeutic Drug Monitoring of Gentamicin Peak Concentrations in Critically Ill Patients","volume":"39","author":"Hodiamont","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/FTD.0000000000000900","article-title":"Bayesian Forecasting for Intravenous Tobramycin Dosing in Adults With Cystic Fibrosis Using One Versus Two Serum Concentrations in a Dosing Interval","volume":"43","author":"Drennan","year":"2021","journal-title":"Ther. Drug Monit."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.5694\/j.1326-5377.2011.tb02973.x","article-title":"Antibiotic resistance is an emerging threat to public health: An urgent call to action at the Antimicrobial Resistance Summit 2011","volume":"194","author":"Gottlieb","year":"2011","journal-title":"Med. J. Aust."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/510393","article-title":"Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship","volume":"44","author":"Dellit","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.3390\/ijerph10094274","article-title":"Strategies to minimize antibiotic resistance","volume":"10","author":"Lee","year":"2013","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1128\/CMR.18.4.638-656.2005","article-title":"Antimicrobial stewardship programs in health care systems","volume":"18","author":"MacDougall","year":"2005","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1310\/hpj4708-608","article-title":"Implementation of an antimicrobial stewardship program in a community hospital: Results of a three-year analysis","volume":"47","author":"Michaels","year":"2012","journal-title":"Hosp. Pharm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1093\/cid\/ciu542","article-title":"Core elements of hospital antibiotic stewardship programs from the Centers for Disease Control and Prevention","volume":"59","author":"Pollack","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","first-page":"150","article-title":"In silico pharmacokinetic study of vancomycin using PBPK modeling and therapeutic drug monitoring","volume":"22","author":"Ferreira","year":"2021","journal-title":"Curr. Drug Metab."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Ferreira, A., Lapa, R., and Vale, N. (2019). Combination of Gemcitabine with Cell-Penetrating Peptides: A Pharmacokinetic Approach Using In Silico Tools. Biomolecules, 9.","DOI":"10.3390\/biom9110693"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40203-021-00083-0","article-title":"Clinical pharmacokinetic study of latrepirdine via in silico sublingual administration","volume":"9","author":"Santos","year":"2021","journal-title":"In Silico Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"ref_38","unstructured":"(2021, February 01). Amikacin. Available online: https:\/\/go.drugbank.com\/drugs\/DB00479."},{"key":"ref_39","unstructured":"(2021, February 01). Gentamicin. Available online: https:\/\/go.drugbank.com\/drugs\/DB00798."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/j.1469-0691.2009.03074.x","article-title":"Pharmacokinetics of gentamicin in critically ill patients: Pilot study evaluating the first dose","volume":"16","author":"Martins","year":"2010","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_41","unstructured":"(2021, February 01). Tobramycin. Available online: https:\/\/go.drugbank.com\/drugs\/DB00684."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jac\/dkf168","article-title":"Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis","volume":"50","author":"Aminimanizani","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_43","unstructured":"(2021, February 01). Tobramycin for Injection. Available online: https:\/\/reference.medscape.com\/drug\/nebcin-injection-tobramycin-342521#10."},{"key":"ref_44","unstructured":"(2021, February 01). Vancomycin. Available online: https:\/\/go.drugbank.com\/drugs\/DB00512."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40262-019-00741-9","article-title":"Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies","volume":"58","author":"Miller","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/psp4.33","article-title":"Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK","volume":"4","author":"Wagner","year":"2015","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Kovar, L., Schr\u00e4pel, C., Selzer, D., Kohl, Y., Bals, R., Schwab, M., and Lehr, T. (2020). Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12060578"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Fuhr, L.M., Marok, F.Z., Hanke, N., Selzer, D., and Lehr, T. (2021). Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug\u2013Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13020270"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3389\/fphar.2021.630904","article-title":"Comparing Predictions of a PBPK Model for Cyclosporine With Drug Levels From Therapeutic Drug Monitoring","volume":"12","author":"Zapke","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/cpt.2021","article-title":"Physiologically based pharmacokinetic modeling of central nervous system pharmacokinetics of CDK4\/6 inhibitors to guide selection of drug and dosing regimen for brain cancer treatment","volume":"109","author":"Li","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/psp4.12605","article-title":"Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator","volume":"10","author":"Wang","year":"2021","journal-title":"CPT Pharmacomet. Syst. Pharmacol."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/11\/11\/1130\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:22:03Z","timestamp":1760167323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/11\/11\/1130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,23]]},"references-count":51,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["life11111130"],"URL":"https:\/\/doi.org\/10.3390\/life11111130","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,23]]}}}